Clinical Research Directory
Browse clinical research sites, groups, and studies.
Time Required to Dissolve Urate Deposits
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
Gout is characterized by episodes of acute arthritis of the lower limbs due to intermittent activation of innate immunity in the joints where urate crystals have formed. These crystals occur when serum urate (SUA) levels have been above 70 mg/L for many years. They can be dissolved by lowering SUA levels to at least 60 mg/L (treat-to-target - T2T - strategy). Once the crystals are dissolved, patients are no longer symptomatic and are considered to be in remission (treat-to-dissolve - T2D - strategy). The presence of crystals and their dissolution during treatment can be monitored by repeated ultrasound (US) scans of the feet and knees. The time required for complete dissolution varies from patient to patient. ReViGore40 is a cohort designed to i) determine the time to complete dissolution of urate deposits in joints when SUA levels are maintained below 40 mg/L, ii) determine the factors (clinical, biological, genetic) associated with the time required for complete dissolution of urate deposits within joints.
Official title: Time Required to Dissolve Urate Deposits in Patients With Gout
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
250
Start Date
2024-09-24
Completion Date
2032-09-24
Last Updated
2026-02-19
Healthy Volunteers
No
Conditions
Interventions
Standard X-Rays
\- Standard X-Rays: feet (Month 0)
Ultrasound
\- Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.
DECT of feet
DECT of feet: in tophaceous patients only (Month 0, Month 24)
DNA sample
DNA will be collected at Month 0
Serum collection
\- Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.
Locations (1)
APHP, Lariboisière Hospital, Rheumatology departement
Paris, France